2.1
Atogepant (Aquipta, Abbvie) is indicated for the 'acute treatment of migraine with or without aura in adults'.
2 Information about atogepant
Marketing authorisation indication
2.2
Atogepant is also indicated for the 'prophylaxis of migraine in adults who have at least 4 migraine days per month'. This is covered in NICE's technology appraisal guidance on atogepant for preventing migraine.
Dosage in the marketing authorisation
2.3
The dosage schedule is available in the summary of product characteristics for atogepant.
Price
2.4
The list price of atogepant 60 mg is £25.78 for a 2 tablet pack and £90.23 for a 7 tablet pack (excluding VAT, from the company submission). The list price of atogepant 28 x 60 mg tablets is £182.16 (excluding VAT; BNF online, accessed May 2026).
2.5
Costs may vary in different settings because of negotiated procurement discounts.
Sustainability
2.6
For information, the Carbon Reduction Plan for UK carbon emissions is published on AbbVie's policy webpage.